Recent Company News

• 05:59 AM ET Apr 29, 2026
  

  Transcript Intelligence: Sandoz Group Q1 Sales and Revenue Guidance

• 05:58 AM ET Apr 29, 2026
  

  Transcript Intelligence: Sandoz Group Q1 Sales and Revenue Q&A

• 05:58 AM ET Apr 29, 2026
  

  Transcript Intelligence: Sandoz Group Q1 Sales and Revenue Themes

• 01:09 AM ET Apr 29, 2026
  

  Sandoz Group reports Q1 revenue $2.76B vs FactSet $2.74B [3 est, $2.66-2.80B] (CHF 62.66, 0.00)

• 04:19 AM ET Apr 22, 2026
  

  Japan approves rituximab biosimilar of Kyowa Kirin's partner Sandoz KK for two additional nephrotic syndrome-related indications (¥2391.0000, 0)

• 04:52 PM ET Apr 01, 2026
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 08:48 AM ET Apr 01, 2026
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 12:43 AM ET Apr 01, 2026
  

  Sandoz Group initiated buy at Goldman Sachs (CHF 61.74, 0.00)

• 01:00 AM ET Mar 23, 2026
  

  Sandoz Group downgraded to sector perform from outperform at RBC Capital Markets (CHF 60.80, 0.00)

• 03:35 AM ET Mar 18, 2026
  

  Sandoz Group announces major license, development and commercialization partnership agreement on up to five biosimilars with Samsung Bioepis Co., Ltd (CHF 62.90, 0.00)